Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2023; 15(5): 666-674
Published online May 27, 2023. doi: 10.4254/wjh.v15.i5.666
Fatty liver and celiac disease: Why worry?
Janaina Luz Narciso-Schiavon, Leonardo Lucca Schiavon
Janaina Luz Narciso-Schiavon, Leonardo Lucca Schiavon, Department of Internal Medicine, Gastroenterology Division, Federal University of Santa Catarina, Florianópolis 88040-900, Santa Catarina, Brazil
Author contributions: Narciso-Schiavon JL designed the research, collected clinical data, analyzed the data and wrote the paper; Schiavon LL designed the research and reviewed the paper; all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All authors do not have any conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Janaina Luz Narciso-Schiavon, PhD, Associate Professor, Department of Internal Medicine, Gastroenterology Division, Federal University of Santa Catarina, Rua Maria Flora Pasewang S/N – Hospital Universitário 3º andar – Depto Clínica Médica - Trindade, Florianópolis 88040-900, Santa Catarina, Brazil. janaina.narciso@uol.com.br
Received: January 17, 2023
Peer-review started: January 17, 2023
First decision: February 21, 2023
Revised: February 27, 2023
Accepted: April 18, 2023
Article in press: April 18, 2023
Published online: May 27, 2023
Processing time: 126 Days and 16.1 Hours
Abstract

Celiac disease (CD) is a chronic inflammatory intestinal disorder mediated by the ingestion of gluten in genetically susceptible individuals. Liver involvement in CD has been widely described, and active screening for CD is recommended in patients with liver diseases, particularly in those with autoimmune disorders, fatty liver in the absence of metabolic syndrome, noncirrhotic intrahepatic portal hypertension, cryptogenic cirrhosis, and in the context of liver transplantation. Non-alcoholic fatty liver disease is estimated to affect approximately 25% of the world’s adult population and is the world’s leading cause of chronic liver disease. In view of both diseases’ global significance, and to their correlation, this study reviews the available literature on fatty liver and CD and verifies particularities of the clinical setting.

Keywords: Fatty liver; Non-alcoholic fatty liver disease; Celiac disease; Transaminases; Aspartate aminotransferase; Alanine aminotransferase

Core Tip: In view of fatty liver and celiac disease (CD) global significance, and to their correlation, this study reviews the available literature on fatty liver and CD and verifies particularities of the clinical setting.